Timeline

1902 – Statens Serum Institut is founded: The origin of SSI Diagnostica Group’s scientific legacy.

1938 – Pneumococcus: Statens Serum Institut develops sera for treatment of pneumococcal infections at a time where antibiotics and penicillin was not widely available, providing patients with life-saving treatment

1989 – TECHLAB is founded: Marks the beginning of SSI Diagnostica Group’s portfolio of gastric products in intestinal inflammation, c. diff, h. pylori, parasites, etc.

1992 – First FDA approval: TECHLAB’s first FDA-cleared assay, launching decades of C. difficile innovation and 14 more gastric FDA approvals within 9 years.

1998 – SSI Diagnostica spun out as an independent business unit: Spun out as a standalone business unit to focus on diagnostic innovation and commercialization.

1999 – CTK Biotech founded: Marks the beginning of SSI Diagnostica Group’s bloodborne product portfolio, and high-quality products for use in third world countries

2000s – QUIK CHEK technology introduced: In early 2000s, TECHLAB develops a new technology; QUIK CHEK, which would come to include more than 10 additionally FDA approved assays over the coming years

2005 – Beijing Genesee Biotech facility established: Founding of our manufacturing capabilities in China

2005 – First dengue assay: CTK Biotech develops the Dengue IgG/IgM rapid test, becoming the first dengue rapid test in the group, and starts supplying the world with diagnostic solutions in a disease that is rapidly spreading

2007 – 2013 WHO approvals for Malaria test: CTK Biotech starts to get WHO approved malaria test to support public health in tropical and low-resource settings

2009 – FDA approval of C. DIFF QUIK CHEK COMPLETE: Solidifies the group’s leadership in C. difficile testing, making the QUIK CHEK COMPLETE a flagship in our QUIK CHEK technology and a global frontrunner in C. difficile testing.

2014: ImmuView P&L developed: A breakthrough in simultaneous pneumococcus and legionella antigen detection, becoming a flagship product in our respiratory portfolio, enabling fast and accurate diagnosis for patients worldwide SSI Diagnostica acquired by Adelis Equity Partners Marked a new era of strategic investments and expansion

2020: CTK Biotech and BGB acquired by Adelis, SSI Diagnostica Group formed: Uniting three companies with complementary strength into a global diagnostic group. CTK and BGB brings an extensive portfolio of lifesaving bloodborne diagnostic solutions into the SSID Group portfolio, including Malaria, HIV, Syphilis, Dengue, Hepatitis and much more

2021: COVID-19 Ag Self-test receives WHO EUL approval: First product co-created by CTK and SSI teams, gaining WHO endorsement ahead of Abbot, Roche and Siemens as the FIRST company.

2022: TECHLAB joins SSI Diagnostica Group: TECHLAB adds an extensive gastric product portfolio to SSI Diagnostica Group, adding decades of renowned expertise in products such as C. difficile, H. pylori, foodborne pathogens, intestinal inflammation and parasites.

2023: Group Strategy formation & innovation as one company: All companies formulate a joint strategy and start commercialization of each other’s portfolios in sales channels. New product development and innovation focus on the full group portfolio to develop the best possible products for customers.

2025: Guld Coast Scientific joins SSI Diagnostica Group: Adds a complimentary portfolio of Urea breath test to SSI Diagnostica Groups portfolio. Urea breath tests allow SSID Group to offer a broader range of diagnostic solutions to labs with different preferences and clinical needs.